{{Short description|Chinese biotechnology company}} {{COI|date=August 2022}} {{Infobox company | name = MGI Tech | logo = MGI-new-logo-1024x455.png | image = DNBSEQ-G400.jpg | image_size = 250px | image_caption = MGI's DNBSEQ-G400, a high-throughput DNA sequencing set | native_name = 深圳华大智造科技股份有限公司 | native_name_lang = zh-cn | type = Public | traded_as = {{SSE|688114}}<ref name="Wall Street Journal Stock Quote">{{cite web |url=https://www.wsj.com/market-data/quotes/cn/xshg/688114 |title=Wall Street Journal Stock Quote: MGI Tech Co Ltd |access-date=2024-04-16 |archive-date=2022-09-12 |archive-url=https://web.archive.org/web/20220912182405/https://www.wsj.com/market-data/quotes/cn/xshg/688114 |url-status=live }}</ref> | founder = | area_served = Worldwide | key_people = | industry = Biotechnology | genre = | products = | services = | num_employees = 2,050<ref name="Bloomberg company profile">{{cite web |url=https://www.bloomberg.com/profile/company/688114:CH |title=Bloomberg company profile: MGI Tech Co Ltd |website=Bloomberg News |access-date=2024-04-16 |archive-date=2024-04-16 |archive-url=https://web.archive.org/web/20240416164003/https://www.bloomberg.com/profile/company/688114:CH |url-status=live }}</ref> | revenue = | url = | operating_income = | net_income = | assets = | equity = | parent = MGI Tech | divisions = | subsid = Complete Genomics | homepage = {{Official URL}} | intl = | foundation = {{start date and age|2016}} | location_city = Shenzhen | location_country = China | locations = | caption = | footnotes = }}
'''MGI''' or '''MGI Tech''' is a Chinese biotechnology company,<ref name=":0">{{Cite journal |last1=Belova |first1=Vera |last2=Pavlova |first2=Anna |last3=Afasizhev |first3=Robert |last4=Moskalenko |first4=Viktoriya |last5=Korzhanova |first5=Margarita |last6=Krivoy |first6=Andrey |last7=Cheranev |first7=Valery |last8=Nikashin |first8=Boris |last9=Bulusheva |first9=Irina |last10=Rebrikov |first10=Denis |last11=Korostin |first11=Dmitriy |date=2022-01-12 |title=System analysis of the sequencing quality of human whole exome samples on BGI NGS platform |journal=Scientific Reports |language=en |volume=12 |issue=1 |page=609 |doi=10.1038/s41598-021-04526-8 |pmid=35022470 |pmc=8755732 |bibcode=2022NatSR..12..609B |issn=2045-2322}}</ref> which provides a line of products and technologies that serves the genetic sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in Shenzhen, Guangdong, China.
== History == In 2016, MGI was founded as a subsidiary of BGI Group.<ref>{{Cite web |last=Pennisi |first=Elizabeth |date=June 15, 2022 |title=A $100 genome? New DNA sequencers could be a 'game changer' for biology, medicine |url=https://www.science.org/content/article/100-genome-new-dna-sequencers-could-be-game-changer-biology-medicine |access-date=July 14, 2022 |website=Science |language=en |archive-date=July 14, 2022 |archive-url=https://web.archive.org/web/20220714043514/https://www.science.org/content/article/100-genome-new-dna-sequencers-could-be-game-changer-biology-medicine |url-status=live }}</ref><ref>{{Cite web |last=Regalado |first=Antonio |date=2020-02-26 |title=China's BGI says it can sequence a genome for just $100 |url=https://www.technologyreview.com/2020/02/26/905658/china-bgi-100-dollar-genome/ |access-date=2022-07-14 |website=MIT Technology Review |language=en |archive-date=2022-01-28 |archive-url=https://web.archive.org/web/20220128044444/https://www.technologyreview.com/2020/02/26/905658/china-bgi-100-dollar-genome/ |url-status=live }}</ref> It manufactures high-throughput genetic sequencing systems and other products for use in the life sciences and health care sectors.<ref>{{Cite book |last1=Pilch |first1=Richard |url=https://nonproliferation.org/wp-content/uploads/2021/09/scientific_risk_assessment_genetic_weapon_systems06_cover.pdf |title=Scientific Risk Assessment of Genetic Weapon Systems |last2=Luster |first2=Jill |last3=Pomper |first3=Miles |last4=Shaw |first4=Robert |publisher=Middlebury Institute of International Studies at Monterey |year=2021 |location=Monterey, California |page=41 |access-date=2024-04-16 |archive-date=2024-03-17 |archive-url=https://web.archive.org/web/20240317073122/https://nonproliferation.org/wp-content/uploads/2021/09/scientific_risk_assessment_genetic_weapon_systems06_cover.pdf |url-status=live }}</ref><ref>{{Cite web |last=Yuting |first=Dun |date=2020-06-26 |title=Chinese DNA sequencing company raises a record $1 billion |url=https://asia.nikkei.com/Business/Startups/Chinese-DNA-sequencing-company-raises-a-record-1-billion |access-date=2022-07-14 |website=Nikkei Asia |language=en-GB |archive-date=2022-06-05 |archive-url=https://web.archive.org/web/20220605213120/https://asia.nikkei.com/Business/Startups/Chinese-DNA-sequencing-company-raises-a-record-1-billion |url-status=live }}</ref> As of July 2022, the company's operation is divided into two primary business segments: genetic sequencers and laboratory automation systems.<ref>{{Cite web |title=华大智造(X20636)：基因测序 星辰大海之华大智造__新浪财经_新浪网 |url=https://stock.finance.sina.com.cn/stock/go.php/vReport_Show/kind/search/rptid/694263131706/index.phtml |access-date=2022-07-14 |website=stock.finance.sina.com.cn |archive-date=2022-02-12 |archive-url=https://web.archive.org/web/20220212132434/https://stock.finance.sina.com.cn/stock/go.php/vReport_Show/kind/search/rptid/694263131706/index.phtml |url-status=live }}</ref><ref>{{Cite web |title=ICG-16 {{!}} 华大智造三大核心业务齐发力！全面赋能生命科学产业发展 – SEQ.CN |url=https://www.seqchina.cn/14966.html |access-date=2022-07-14 |website=www.seqchina.cn |archive-date=2022-02-12 |archive-url=https://web.archive.org/web/20220212132520/https://www.seqchina.cn/14966.html |url-status=live }}</ref>
MGI was a subsidiary of BGI Group before, it was spun out and listed on the Shanghai stock exchange in 2022.<ref>{{Cite news |last1=Smyth |first1=Jamie |last2=Sevastopulo |first2=Demetri |date=18 April 2023 |title=Chinese genetics company targets US despite political tensions |url=https://www.ft.com/content/cc905012-f264-4e87-8171-8e7e243c5d51 |url-access=subscription |access-date=2023-04-18 |website=Financial Times |language=en |archive-date=2023-04-18 |archive-url=https://web.archive.org/web/20230418040329/https://www.ft.com/content/cc905012-f264-4e87-8171-8e7e243c5d51 |url-status=live }}</ref>
In May 2020, MGI raised $1 billion in series B funding from IDG Capital and CPE China Fund.<ref>{{Cite web |last1=Yanfeng |first1=Peng |last2=Jia |first2=Denise |title=Coronavirus Testing Equipment Maker MGI Tech Gets $1 Billion Funding - Caixin Global |url=https://www.caixinglobal.com/2020-05-29/coronavirus-testing-equipment-maker-mgi-tech-gets-1-billion-funding-101560398.html |access-date=2022-07-14 |website=Caixin Global |language=en |archive-date=2022-07-04 |archive-url=https://web.archive.org/web/20220704230627/https://www.caixinglobal.com/2020-05-29/coronavirus-testing-equipment-maker-mgi-tech-gets-1-billion-funding-101560398.html |url-status=live }}</ref><ref>{{Cite book |last=Micalo |first=Silvia |url=https://books.google.com/books?id=rUyBEAAAQBAJ&dq=%22MGI+Tech%22+sequencing&pg=PT268 |title=Healthtech Innovation: How Entrepreneurs Can Define and Build the Value of Their New Products |date=2022-10-03 |publisher=CRC Press |isbn=978-1-000-73722-6 |language=en |access-date=2022-09-06 |archive-date=2024-04-16 |archive-url=https://web.archive.org/web/20240416164003/https://books.google.com/books?id=rUyBEAAAQBAJ&dq=%22MGI+Tech%22+sequencing&pg=PT268#v=onepage&q=%22MGI%20Tech%22%20sequencing&f=false |url-status=live }}</ref> In December 2020, the company submitted its IPO application to Shanghai Stock Exchange STAR Market.<ref>{{Cite web |last=Zhang |first=Huanjia |date=2022-08-29 |title=MGI Tech Planning to go Public in $366M Chinese IPO |url=https://www.genomeweb.com/sequencing/mgi-tech-planning-go-public-366m-chinese-ipo |access-date=2022-09-03 |website=GenomeWeb |language=en |archive-date=2022-09-03 |archive-url=https://web.archive.org/web/20220903141454/https://www.genomeweb.com/sequencing/mgi-tech-planning-go-public-366m-chinese-ipo |url-status=live }}</ref><ref>{{Cite web |last1=Law |first1=Kenneth |last2=Lin |first2=Tony |date=September 2021 |title=2021 China Life Sciences and Healthcare M&A Whitepaper |url=https://www2.deloitte.com/content/dam/Deloitte/cn/Documents/life-sciences-health-care/deloitte-cn-lshc-2021-china-lshc-ma-market-whitepaper-en-210927.pdf |archive-url=https://web.archive.org/web/20221130205928/https://www2.deloitte.com/content/dam/Deloitte/cn/Documents/life-sciences-health-care/deloitte-cn-lshc-2021-china-lshc-ma-market-whitepaper-en-210927.pdf |access-date=2022-09-03 |website=Deloitte |pages=7–8 |archive-date=2022-11-30 |url-status=live }}</ref> In September 2021, the company has won the approval for its IPO on Shanghai Stock Exchange STAR Market's high-tech board.<ref>{{Cite web |title=BGI's Gene Sequencer Spin-Off Approved for Shanghai IPO |url=https://www.caixinglobal.com/2021-09-03/bgis-gene-sequencer-spin-off-approved-for-shanghai-ipo-101768561.html |access-date=2024-04-16 |website=Caixin |language=en |archive-date=2023-12-16 |archive-url=https://web.archive.org/web/20231216080120/https://www.caixinglobal.com/2021-09-03/bgis-gene-sequencer-spin-off-approved-for-shanghai-ipo-101768561.html |url-status=live }}</ref>
In 2024, MGI lost more than a third of its market capitalization after the US Congress introduced legislation to prohibit American health data being sent to China.<ref>{{Cite news |date=April 15, 2024 |title=America hits Chinese biotech—and its own drugmakers |url=https://www.economist.com/business/2024/04/15/america-hits-chinese-biotech-and-its-own-drugmakers |url-access=subscription |access-date=2024-04-16 |newspaper=The Economist |issn=0013-0613 |archive-date=2024-04-16 |archive-url=https://web.archive.org/web/20240416005141/https://www.economist.com/business/2024/04/15/america-hits-chinese-biotech-and-its-own-drugmakers |url-status=live }}</ref>
In 2024, MGI opens Customer Experience Center in Brazil. <ref>{{Cite news |date=April 22, 2024 |title=MGI Tech abre centro de experiência do cliente no Brasil |url=https://medicinasa.com.br/mgi-brasil/ |access-date=2024-04-22 |newspaper=Medicina S/A |language=pt|url-status=live }}</ref>
In 2025, Swiss biotech incubator firm Swiss Rockets has entered into an exclusive licensing agreement with MGI Tech and its US subsidiary Complete Genomics granting the company the rights to develop and commercialize next-generation sequencers based on the MGI Tech/Complete Genomics' CoolMPS technology in most parts of the world. <ref>{{Cite news |date=Oct 28, 2025 |title=Swiss Rockets Exclusively Licenses Sequencing Chemistry From MGI Tech, Complete Genomics |url=https://www.genomeweb.com/business-news/swiss-rockets-exclusively-licenses-sequencing-chemistry-mgi-tech-complete-genomics |access-date=2025-10-28 |newspaper=GenomeWeb |archive-date=2025-10-30 |archive-url=https://web.archive.org/web/20251030131226/https://www.genomeweb.com/business-news/swiss-rockets-exclusively-licenses-sequencing-chemistry-mgi-tech-complete-genomics |url-status=bot: unknown }}</ref>
== Subsidiaries ==
=== Complete Genomics === In March 2013, Complete Genomics was acquired by BGI Group.<ref>{{Cite web |date=2012-09-17 |title=Complete Genomics, BGI Agree to $117.6M Merger |url=https://www.genomeweb.com/clinical-sequencing/complete-genomics-bgi-agree-1176m-merger |access-date=2022-07-14 |website=GenomeWeb |language=en |archive-date=2022-12-05 |archive-url=https://web.archive.org/web/20221205202521/https://www.genomeweb.com/clinical-sequencing/complete-genomics-bgi-agree-1176m-merger |url-status=live }}</ref> After the acquisition, Complete Genomics moved to San Jose, and in June 2018 became part of MGI.<ref>{{Cite news |last1=Campbell |first1=Matthew |last2=Lyu |first2=Dong |date=2019-11-13 |title=China's Genetics Giant Wants to Tailor Medicine to Your DNA |language=en |work=Bloomberg Asia Edition |url=https://www.bloomberg.com/news/features/2019-11-13/chinese-genetics-giant-bgi-wants-to-tailor-medicine-to-your-dna |access-date=2022-09-03 |archive-date=2022-04-17 |archive-url=https://web.archive.org/web/20220417032459/https://www.bloomberg.com/news/features/2019-11-13/chinese-genetics-giant-bgi-wants-to-tailor-medicine-to-your-dna |url-status=live }}</ref><ref>{{Cite web |last1=LeMieux |first1=Julianna |last2=PhD |date=2019-01-11 |title=All Aboard the Genome Express |url=https://www.genengnews.com/insights/all-aboard-the-genome-express/ |access-date=2022-07-14 |website=GEN - Genetic Engineering and Biotechnology News |language=en-US |archive-date=2022-07-14 |archive-url=https://web.archive.org/web/20220714063905/https://www.genengnews.com/insights/all-aboard-the-genome-express/ |url-status=live }}</ref> The acquisition was one of the outcomes of $1.5 billion 'collaborative funds' i.e., '10 years loan' which was initially provided by China Development Bank to acquire all 128 of Illumina, Inc.'s newest and fastest next-generation sequencers including HiSeq 2000.<ref>{{Cite journal |last1=Wang |first1=Kai |last2=Shen |first2=Xiaobai |last3=Williams |first3=Robin |date=2021-07-03 |title=Sequencing BGI: the evolution of expertise and research organisation in the world's leading gene sequencing facility |journal=New Genetics and Society |volume=40 |issue=3 |pages=305–330 |doi=10.1080/14636778.2020.1843148 |s2cid=229445267 |issn=1463-6778 |hdl=20.500.11820/fdccac07-cd53-42df-ac40-62842218dc76 |hdl-access=free }}</ref>
== Research and development == The company is known for manufacturing DNA sequencers based on low-cost DNA nanoball sequencing technologies which was refined further after the acquisition of Complete Genomics.<ref>{{Cite journal |last1=Anslan |first1=Sten |last2=Mikryukov |first2=Vladimir |last3=Armolaitis |first3=Kęstutis |last4=Ankuda |first4=Jelena |last5=Lazdina |first5=Dagnija |last6=Makovskis |first6=Kristaps |last7=Vesterdal |first7=Lars |last8=Schmidt |first8=Inger Kappel |last9=Tedersoo |first9=Leho |date=2021-09-30 |title=Highly comparable metabarcoding results from MGI-Tech and Illumina sequencing platforms |journal=PeerJ |language=en |volume=9 |article-number=e12254 |doi=10.7717/peerj.12254 |issn=2167-8359 |pmc=8491618 |pmid=34703674 |doi-access=free}}</ref><ref>{{Cite book |last1=Kaspers |first1=Bernd |url=https://books.google.com/books?id=5HENEAAAQBAJ&dq=%22MGI+Tech%22+sequencing&pg=PA289 |title=Avian Immunology |last2=Schat |first2=Karel A. |last3=Göbel |first3=Thomas |last4=Vervelde |first4=Lonneke |date=2021-12-05 |publisher=Academic Press |isbn=978-0-12-819071-5 |language=en |access-date=2022-09-06 |archive-url=https://web.archive.org/web/20240416163209/https://books.google.com/books?id=5HENEAAAQBAJ&dq=%22MGI+Tech%22+sequencing&pg=PA289 |archive-date=2024-04-16 |url-status=live}}</ref> The refinement included combinatorial probe anchor synthesis technologies which involves loading DNA nanoballs (DNBs) onto a patterned array chip using a fluidic system. Subsequently, a sequencing primer is added to the adaptor region of the DNBs in order to hybridize them.<ref>{{Cite journal |last1=Li |first1=Zhuokun |last2=Wang |first2=Xiaojue |last3=Xu |first3=Dongyang |last4=Zhang |first4=Dengwei |last5=Wang |first5=Dan |last6=Dai |first6=Xuechen |last7=Wang |first7=Qi |last8=Li |first8=Zhou |last9=Gu |first9=Ying |last10=Ouyang |first10=Wenjie |last11=Zhao |first11=Shuchang |last12=Huang |first12=Baoqian |last13=Gong |first13=Jian |last14=Zhao |first14=Jing |last15=Chen |first15=Ao |date=2020-07-31 |title=DNB-based on-chip motif finding: A high-throughput method to profile different types of protein-DNA interactions |journal=Science Advances |volume=6 |issue=31 |article-number=eabb3350 |doi=10.1126/sciadv.abb3350 |issn=2375-2548 |pmc=7399529 |pmid=32789179|bibcode=2020SciA....6.3350L }}</ref>
In 2023, MGI dubbed DNBSEQ-T20 which can read up to 50,000 human genomes a year. And the cost of reading each genome will be as low as $100. <ref>{{Cite journal |date=2023-02-07 |title=Chinese DNA giant’s U.S. affiliate looks to rival Illumina, touting $100 genome and high-power sequencers|journal=StatNews |language=en |url=https://www.statnews.com/2023/02/07/chinese-dna-giants-u-s-affiliate-looks-to-rival-illumina-touting-100-genome-and-high-power-sequencers/}}</ref><ref>{{Cite journal |date=2023-02-07 |title=MGI Breaks the $100 genome barrier, barely|journal=San Diego Omics |language=en |url=https://sandiegomics.com/mgi-breaks-the-100-genome-barrier-barely/}}</ref>
In 2025, MGI Tech unveils DNBSEQ-T1+. The DNBSEQ-T1+ is a next-generation mid-throughput sequencer that completes a paired end 150 sequencing workflow in just 24 hours with Q40 accuracy.<ref>{{Cite journal |date=2025-02-28 |title=MGI Tech unveils high-speed sequencing solutions at AGBT 2025 |journal=Korean Biomedical Review |language=en |url=https://www.koreabiomed.com/news/articleView.html?idxno=26782}}</ref>
In 2025, MGI Tech touts world’s fastest gene sequencer: 10 minutes to read a genome. The company said at a launch event that the DNBSEQ-T7+ can sequence 144 human genomes a day, or one every 10 minutes. <ref>{{Cite journal |date=2025-09-09 |title=China’s MGI Tech touts world’s fastest gene sequencer: 10 minutes to read a genome |journal=South China Morning Post |language=en |url=https://www.scmp.com/tech/big-tech/article/3324917/chinas-mgi-tech-touts-worlds-fastest-gene-sequencer-10-minutes-read-genome }}</ref>
== Criticism == On October 31, 2019, the Chairman of the Senate Finance Committee, Chuck Grassley, and Senator Marco Rubio wrote a joint letter to Alex Azar, the Secretary of the Department of Health and Human Services and Seema Verma, the Administrator of the Centers for Medicare & Medicaid Services (CMS) raised their concerns against MGI, regarding the circumstances under which the CMS may finance it to process American citizens' genomic or exome data.<ref>{{Cite web |title=Grassley, Rubio Seek Answers on HHS Funded Genetic Testing Connected to China, Russia {{!}} The United States Senate Committee on Finance |url=https://www.finance.senate.gov/chairmans-news/grassley-rubio-seek-answers-on-hhs-funded-genetic-testing-connected-to-china-russia |access-date=2022-09-12 |website=www.finance.senate.gov |language=en |archive-date=2022-09-12 |archive-url=https://web.archive.org/web/20220912161434/https://www.finance.senate.gov/chairmans-news/grassley-rubio-seek-answers-on-hhs-funded-genetic-testing-connected-to-china-russia |url-status=live }}</ref>
MGI asserted that it is "a supplier of instruments and consumables for customers to use in their own labs" and does not provide any genomic sequencing services. "MGI does not own, control, handle, or even access samples or genetic data, only MGI's customers do. There is no risk that MGI will have access to any health records or genetic data from customers," the company stated.<ref>{{cite web |last1=Huanjia |first1=Zhang |title=MGI Tech Heads Full Steam Into US Market Despite Data Security Accusations, Image Problems |url=https://www.genomeweb.com/sequencing/mgi-tech-heads-full-steam-us-market-despite-data-security-accusations-image-problems |website=GenomeWeb |publisher=GenomeWeb |access-date=19 December 2022}}</ref>
== Litigation ==
=== Patents infringement lawsuit === In November 2021, a federal jury in California concluded that MGI America (in its capacity as an affiliate of BGI Group) had infringed Illumina, Inc.'s patents. Accordingly, they awarded Illumina damages of $8 million.<ref>{{Cite web |last=Albarazi |first=Hannah |title=Jury Says BGI Owes Illumina $8M For Infringing DNA Patents - Law360 |url=https://www.law360.com/articles/1443178/jury-says-bgi-owes-illumina-8m-for-infringing-dna-patents |access-date=2022-07-14 |website=Law360 |language=en |archive-date=2022-07-14 |archive-url=https://web.archive.org/web/20220714064217/https://www.law360.com/articles/1443178/jury-says-bgi-owes-illumina-8m-for-infringing-dna-patents |url-status=live }}</ref>
In March 2022, Illumina persuaded a U.S. District Judge to prolong the restriction on MGI America selling its CoolMPS sequencers in the United States for six months until August 2022, when Illumina's patent expires.<ref>{{Cite news |last=Brittain |first=Blake |date=2022-03-29 |title=Illumina wins extended U.S. ban on BGI gene-sequencer sales |language=en |work=Reuters |url=https://www.reuters.com/legal/transactional/illumina-wins-extended-us-ban-bgi-gene-sequencer-sales-2022-03-28/ |access-date=2022-07-14 |archive-date=2022-07-14 |archive-url=https://web.archive.org/web/20220714064216/https://www.reuters.com/legal/transactional/illumina-wins-extended-us-ban-bgi-gene-sequencer-sales-2022-03-28/ |url-status=live }}</ref>
=== "Two-channel" DNA sequencing lawsuit === Complete Genomics, a research subsidiary of MGI, filed a lawsuit in May 2019, alleging that Illumina's "two-channel" DNA sequencing chemistry violates two patents for the technology that deduces the identification of each nucleotide from two signals. The NovaSeq 6000, the NextSeq 500/550/550x, and 1000/2000 Series, as well as the MiniSeq, were all the focus of the lawsuit against Illumina. Additionally, it targeted Illumina's cluster generation & sequencing, and library preparation kits, all of which are interoperable with one or more platforms.<ref>{{Cite web |last=Yasiejko |first=Christopher |date=2022-05-09 |title=Illumina Owes BGI $333.8 Million Over Gene-Sequencer Patents (2) |url=https://news.bloomberglaw.com/ip-law/illumina-must-pay-bgi-333-8-million-over-gene-sequencer-patents |access-date=2022-07-14 |website=Bloomberg Law |language=en |archive-date=2022-05-10 |archive-url=https://web.archive.org/web/20220510040806/https://news.bloomberglaw.com/ip-law/illumina-must-pay-bgi-333-8-million-over-gene-sequencer-patents |url-status=live }}</ref>
In May 2022, a jury in Delaware concluded that Illumina's "two-channel" sequencing chemistry infringes on two patents owned by MGI Tech through its subsidiary Complete Genomics. As a result of this finding, the jury awarded $333.8 million in damages to the company. The jury also dismissed Illumina's assertions that the patents were invalid. The verdict also invalidated three of Illumina's patents that the firm had asserted in a countersuit claiming MGI Tech had infringed on Illumina's patents.<ref>{{Cite news |last=Brittain |first=Blake |date=2022-05-07 |title=Illumina ordered to pay BGI subsidiary $333 million in DNA-sequencing patent case |language=en |work=Reuters |url=https://www.reuters.com/technology/illumina-ordered-pay-chinese-company-333-million-gene-sequencing-patent-case-2022-05-06/ |access-date=2022-07-14 |archive-date=2022-05-11 |archive-url=https://web.archive.org/web/20220511140644/https://www.reuters.com/technology/illumina-ordered-pay-chinese-company-333-million-gene-sequencing-patent-case-2022-05-06/ |url-status=live }}</ref>
== References == {{reflist}}
== External links ==
* {{Official website}}
Category:Laboratory equipment manufacturers Category:Manufacturing companies based in Shenzhen Category:Research support companies Category:Chinese companies established in 2016 Category:Biotechnology companies of China Category:Genomics companies Category:DNA sequencing Category:2016 in Shenzhen